Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

ACELYRIN (SLRN)

ACELYRIN Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:SLRN
DateTimeSourceHeadlineSymbolCompany
10/02/202514:11PR Newswire (US)Kuehn Law Encourages NVRO, SLRN, TGI, and PTMN Investors to Contact Law FirmNASDAQ:SLRNACELYRIN Inc
07/02/202522:00Edgar (US Regulatory)Form 425 - Prospectuses and communications, business combinationsNASDAQ:SLRNACELYRIN Inc
07/02/202520:22PR Newswire (US)ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of ACELYRIN, INC.NASDAQ:SLRNACELYRIN Inc
06/02/202522:19Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SLRNACELYRIN Inc
06/02/202521:15GlobeNewswire Inc.Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated DiseasesNASDAQ:SLRNACELYRIN Inc
06/02/202521:15GlobeNewswire Inc.Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated DiseasesNASDAQ:SLRNACELYRIN Inc
31/01/202521:26Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SLRNACELYRIN Inc
24/01/202523:05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SLRNACELYRIN Inc
06/01/202521:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SLRNACELYRIN Inc
06/01/202521:00GlobeNewswire Inc.ACELYRIN, INC. Announces Additional Phase 2 Data and Phase 3 Program Design for Lonigutamab in Thyroid Eye DiseaseNASDAQ:SLRNACELYRIN Inc
03/01/202501:00GlobeNewswire Inc.ACELYRIN, INC. to Host Virtual Investor Event to Share new Phase 2 Data and Phase 3 Program Design for Subcutaneous LonigutamabNASDAQ:SLRNACELYRIN Inc
10/12/202421:34Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SLRNACELYRIN Inc
10/12/202421:30GlobeNewswire Inc.ACELYRIN, INC. Announces Topline Results From Phase 2b/3 Study of Izokibep for the Treatment of UveitisNASDAQ:SLRNACELYRIN Inc
13/11/202422:26Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:SLRNACELYRIN Inc
13/11/202421:03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SLRNACELYRIN Inc
13/11/202421:01Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SLRNACELYRIN Inc
13/11/202421:00GlobeNewswire Inc.ACELYRIN, INC. Reports Third Quarter 2024 Financial Results and Recent HighlightsNASDAQ:SLRNACELYRIN Inc
08/11/202419:17Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:SLRNACELYRIN Inc
06/11/202421:00GlobeNewswire Inc.ACELYRIN, INC. to Report Third Quarter 2024 Financial Results and Corporate Update on November 13, 2024NASDAQ:SLRNACELYRIN Inc
04/11/202421:11Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:SLRNACELYRIN Inc
24/10/202418:02Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:SLRNACELYRIN Inc
16/10/202411:00GlobeNewswire Inc.ACELYRIN, INC. Forms Scientific and Patient Advisory Board Featuring Leading Voices in Thyroid Eye DiseaseNASDAQ:SLRNACELYRIN Inc
19/09/202411:00GlobeNewswire Inc.ACELYRIN, INC. Announces Positive Results from Global Phase 3 Clinical Trial of Izokibep in Hidradenitis Suppurativa to be Highlighted in Late-Breaking Oral Presentation at EADV 2024NASDAQ:SLRNACELYRIN Inc
10/09/202411:00GlobeNewswire Inc.ACELYRIN, INC. Announces Positive Proof-of-Concept Data From Phase 1/2 Clinical Trial of Lonigutamab as a Subcutaneous Treatment for Thyroid Eye Disease to be Presented at 42nd Annual Meeting of European Society of Ophthalmic Plastic and Reconstructive SurNASDAQ:SLRNACELYRIN Inc
22/08/202411:00GlobeNewswire Inc.ACELYRIN, INC. to Participate in Upcoming Investor ConferencesNASDAQ:SLRNACELYRIN Inc
13/08/202420:18Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SLRNACELYRIN Inc
13/08/202420:14Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SLRNACELYRIN Inc
13/08/202420:00GlobeNewswire Inc.ACELYRIN, INC. Announces Positive Phase 3 Data for Izokibep in Hidradenitis Suppurativa; Focuses Strategy on Lonigutamab and Reports Second Quarter 2024 Financial ResultsNASDAQ:SLRNACELYRIN Inc
06/08/202420:30GlobeNewswire Inc.ACELYRIN, INC. to Report Second Quarter 2024 Financial Results and Corporate Update on August 13, 2024NASDAQ:SLRNACELYRIN Inc
11/06/202421:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SLRNACELYRIN Inc
 Showing the most relevant articles for your search:NASDAQ:SLRN